Salvato in:
| Autori principali: | , , , , , , , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2026
|
| Soggetti: | |
| Accesso online: | https://onlinelibrary.wiley.com/doi/10.1002/ccd.70549 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Sommario:
- Long‐Term Outcomes After Percutaneous Coronary Intervention With the Polymer‐Free Biolimus‐Coated BioFreedom Stent Versus the Biodegradable‐Polymer Sirolimus‐Eluting Orsiro Stent in Patients With Acute Coronary Syndromes Manijeh Noori Evald Høj Christiansen Mikkel Hougaard Ashkan Eftekhari Lars Jakobsen Julia Ellert Rebekka Vibjerg Jensen Kirstine Nørregaard Hansen Nicolaj Brejnholt Støttrup Bent Raungaard Jens Flensted Lassen Johnny Kahlert Anders Junker Lisette Okkels Jensen Catheterization and Cardiovascular Interventions ABSTRACT Background The polymer‐free biolimus A9‐coated BioFreedom stent (BF‐BCS) releases a lipophilic drug that may provide a potent anti‐inflammatory effect in patients with acute coronary syndromes (ACS). Five‐year efficacy and safety of BF‐BCS were compared to the ultrathin strut biodegradable polymer sirolimus‐eluting Orsiro stent (O‐SES) in ACS patients. Methods From SORT OUT IX, 1672 ACS patients were analyzed (821 treated with BF‐BCS and 851 with O‐SES); 764 (46%) presented with ST‐segment‐elevation myocardial infarction (STEMI) and 907 (54%) with non‐STEMI. Endpoints were target lesion failure (TLF) (a composite of cardiac death, target lesion myocardial infarction [MI], target lesion revascularization [TLR]) and definite stent thrombosis (ST) at 5‐years. Results At 5‐years, TLF in ACS patients did not differ significantly between BF‐BCS and O‐SES (12.5% vs. 10.8%; rate ratio (RR) 1.12; 95% confidence interval (CI): 0.84–1.49). Cardiac death, target lesion MI, and definite ST rates were similar. TLR was higher with BF‐BCS compared to O‐SES within the first year (2.9% vs. 1.2%, RR 2.37; 95% CI: 1.13–4.99), but this difference was not maintained at 5‐year follow‐up (6.2% vs. 4.3%; RR 1.42; 95% CI: 0.92–2.18). The increased risk of TLR within the first year was driven by increased risk of TLR in STEMI patients treated with BF‐BCS compared to O‐SES (2.5% vs. 0.3%, RR 9.96; 95% CI: 1.26–79.0), while there were no differences in TLR rates in NSTEMI patients. Conclusion At 5‐year follow‐up, TLF did not differ significantly in BF‐BCS or O‐SES treated ACS patients. The increased risk of early TLR in STEMI patients treated with BF‐BCS was not maintained at 5‐year follow‐up. 10.1002/ccd.70549 http://onlinelibrary.wiley.com/termsAndConditions#vor